The maintenance of a Buy rating suggests that Benchmark analyst Mike Hickey remains optimistic about Imax's future performance. However, the reduction in the price target from $24 to $22 may reflect a more cautious outlook on the company's growth prospects or market conditions, which could lead to a neutral short-term impact on the stock price as investors digest the mixed signals.